Prostate Cancer Screening Restricted to 'Few Thousand' High-Risk Individuals

According to the final guidelines issued by scientific advisers, prostate cancer screening via blood test should be restricted exclusively to "a few thousand" men who carry a specific dangerous genetic mutation and have a family history of the disease. The UK’s National Screening Committee has concluded that for all other demographics, the potential harms associated with screening outweigh the benefits.

While acknowledging that testing healthy men for prostate cancer can save lives, the committee highlighted that such interventions often result in treatments that cause significant side effects, including urinary incontinence and erectile dysfunction. The ultimate authority to implement these recommendations lies with health ministers across England, Wales, Scotland, and Northern Ireland.

The prostate gland, located just beneath the bladder, plays a crucial role in male physiology by contributing to seminal fluid production and influencing urinary flow. Prostate cancer remains the most prevalent cancer among men in the UK, claiming approximately 12,000 lives annually. Current screening protocols involve a Prostate Specific Antigen (PSA) blood test, followed by an MRI scan of the prostate if initial results are inconclusive.

A comprehensive review conducted by the National Screening Committee revealed that screening 1,000 men in their 50s would result in only two lives saved from prostate cancer over a 15-year period. Conversely, this process would identify 20 men with cancers so slow-growing that they would not pose a threat even if the individuals lived to be 120 or 150 years old. Despite being harmless, these diagnoses impose a lifelong psychological burden. Of those 20 men, 12 would undergo unnecessary treatments that damage the prostate, potentially harming their sexual function and leading to incontinence that requires the use of absorbent pads.

Professor Sir Mike Richards, the chair of the screening committee and a man living with prostate cancer himself, stated: "Once a prostate cancer is found, we still can't reliably tell which cancers need treatment or which do not – and the treatments available for prostate cancer can cause long-lasting harm."

Consequently, the final advice explicitly rules out screening for the following groups: * The general male population; * Black men, who face double the risk of developing the disease; * Men with a family history of cancer, as the prevalence of the disease makes it difficult to isolate specific risk factors.

The only exception identified is for men possessing the BRCA2 gene variant combined with a family history of breast, ovarian, pancreatic, or prostate cancer. The BRCA2 gene is responsible for DNA repair, and certain mutations increase both the frequency and lethality of cancers. Under the new guidelines, eligible men will be invited for a PSA blood test every two years between the ages of 45 and 61. This initiative will affect only a "few thousand" men annually, though some are already undergoing informal screening through NHS genetics clinics due to known family histories.

The committee emphasized that its stance is subject to change as new data emerges. Ongoing evaluations of emerging technologies, such as improved diagnostic tests and artificial intelligence tools, as well as results from the UK-based Transform trial, could eventually justify broader screening programs. The Transform trial aims to resolve key uncertainties regarding the severity of prostate cancer in black men. While it is established that black men have a higher incidence of the disease, it remains unclear if the cancers are more aggressive, a factor that would influence NHS screening decisions.

Sir Mike expressed hope that "new evidence and new tests and a better understanding of prostate cancer will support wider prostate cancer screening in future," but stressed that "they do need the evidence first."

This review follows a period of intense advocacy involving various charities and prominent figures, including Olympic champion Sir Chris Hoy, who has terminal prostate cancer, as well as former Prime Ministers David Cameron and Rishi Sunak. Other notable supporters include actor Stephen Fry and footballers, whose campaigns highlighted the urgent need for effective screening strategies.

Source: BBC News Generated at: 2026-05-28 11:00:15 UTC